Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic...
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
About this item
Full title
Author / Creator
Qin, Kang , Wang, Kaiwen , Li, Shenduo , Hong, Lingzhi , Padmakumar, Priyadharshini , Waree, Rinsurongkawong , Hubert, Shawna M. , Le, Xiuning , Vokes, Natalie , Rai, Kunal , Vaporciyan, Ara , Gibbons, Don L. , Heymach, John V. , Lee, J. Jack , Woodman, Scott E. , Chung, Caroline , Jaffray, David A. , Altan, Mehmet , Lou, Yanyan and Zhang, Jianjun
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Docetaxel +/− ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether the cancer gene mutation status was associated with clinical benefits from docetaxel +/− ramuci...
Alternative Titles
Full title
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Authors, Artists and Contributors
Author / Creator
Wang, Kaiwen
Li, Shenduo
Hong, Lingzhi
Padmakumar, Priyadharshini
Waree, Rinsurongkawong
Hubert, Shawna M.
Le, Xiuning
Vokes, Natalie
Rai, Kunal
Vaporciyan, Ara
Gibbons, Don L.
Heymach, John V.
Lee, J. Jack
Woodman, Scott E.
Chung, Caroline
Jaffray, David A.
Altan, Mehmet
Lou, Yanyan
Zhang, Jianjun
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10931294
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10931294
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers16050935
